F-1/A: Medicus Pharma Eyes Nasdaq Listing with 1.2 Million Unit Offering

Medicus Pharma Ltd. is seeking to raise capital and list on the Nasdaq through an offering of 1.2 million units, each comprising a common share and a warrant.

Summary

• Medicus Pharma Ltd. is offering 1,200,000 units, each consisting of one common share and one warrant to purchase one common share.
• The warrants are immediately exercisable at a price equal to 100% of the unit price and expire five years from issuance.
• The company has applied to list its common shares and warrants on the Nasdaq Capital Market under the symbols 'MDCX' and 'MDCXW,' respectively.
• A 1-for-3 reverse stock split is planned to be effective around the pricing date of the offering.
• The assumed initial public offering price is $5.06 per unit, based on the TSXV closing price on September 20, 2024, after giving effect to the Share Consolidation.
• Medicus Pharma intends to use the net proceeds to fund a Phase 2 proof of concept clinical trial for SkinJect for basal cell carcinoma treatment and for general corporate purposes.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the risks associated with its development and commercialization. The company is early stage and has significant risks.

Positives

• The company has completed a Phase 1 study of SkinJect.
• SkinJect has the potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Negatives

• There is no assurance that the company will be successful in listing its common shares or warrants on the U.S. Exchange.
• The company had an accumulated deficit of approximately US$24.8 million as of June 30, 2024.

Risks

• The company's financial results may vary significantly from forecasts.
• The progress, timing and completion of clinical trials are subject to risks.
• The company's ability to market and commercialize products is uncertain.
• The company may need additional financing in the future.
• The company operates in a highly competitive industry.
• The company relies on key personnel.
• The company's intellectual property is held under third-party licenses.
• The company's technology may not be successful for its intended use.
• The manufacture of the Product is complex.
• The company relies on external contract research organizations to provide clinical and nonclinical research services.

Future Outlook

The company expects R&D expenses to increase substantially as it advances product candidates into clinical trials and expands its pipeline.

Industry Context

The document highlights the competitive landscape of the pharmaceutical industry, particularly in skin cancer treatments, noting the presence of companies with greater resources and the potential for new therapies to emerge.

Comparison to Industry Standards

• The document mentions that the current standard of care for localized BCC is surgical, either via standard excision or Mohs micrographic surgery.
• It also notes that commonly used topical treatments for BCC currently include: imiquimod; 5-fluorouracil; and tazarotene.
• The document compares the efficacy of imiquimod, 5-fluorouracil, and tazarotene to surgery, noting that imiquimod's efficacy is significantly inferior to surgery, with 84% of imiquimod-treated patients remaining tumor-free after 3-years, compared to 98% of surgically treated patients.

Related Party Transactions

• The company had an agreement with Velocity Fund Management, LLC ('VFM'), an affiliate of a shareholder of the Company, that provided for certain managerial positions to be filled from within VFM.
• On October 18, 2023, the Company signed an agreement with RBx, that provides for certain managerial positions to be filled from within RBx.
• On May 3, 2024, certain directors and officers of the Company purchased $700,000 aggregate principal amount of 2025 Convertible Notes on the same terms as the investors who were not related to the Company.
• On June 28, 2024, the 2025 Convertible Notes were converted into common shares of the Company at a conversion price of US$2.00 per share.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's success depends on the acceptance of its products by healthcare providers and patients.
• Employees are subject to lock-up agreements restricting the sale of their shares.

Next Steps

• The company intends to use the net proceeds from this offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch.
• The company may also use the net proceeds of this offering to expand its exploratory phase 2 clinical trial to a pivotal trial and/or to expand its trials to cover other non-melanoma skin diseases.
• The company will use any remaining net proceeds for general corporate purposes and working capital.

Key Dates

Keywords

Medicus Pharma, SkinJect, Nasdaq, IPO, Warrants, Common Shares, Basal Cell Carcinoma, Clinical Trial, Doxorubicin, Microneedle Array, MDCX, MDCXW